![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
S Kharbanda, Y Emoto, H Kisaki, A Saleem and D Kufe
Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115.
1-beta-D-Arabinofuranosylcytosine (ara-C) is an effective antileukemic agent that misincorporates into DNA. Recent studies have demonstrated that ara-C treatment is associated with transient induction of the c- jun early response gene. The present studies have examined the effects of ara-C on c-jun expression in a phorbol ester-resistant variant of the HL-60 myeloid leukemia cell line, designated HL-525, that is deficient in protein kinase C (PKC)-mediated signal transduction and fails to respond to 12-O-tetradecanoylphorbol-13-acetate with induction of c-jun transcripts. The results demonstrate that treatment of HL-525 cells with ara-C is associated with transcriptional activation of the c- jun gene. We also demonstrate that ara-C treatment is associated with activation of a PKC-like activity. Partial purification of this Ca(2+)- independent activity has demonstrated phosphorylation of synthetic peptides derived from (a) amino acids 4-14 of myelin basic protein and (b) the pseudosubstrate region of PKC (amino acids 19-31), with substitution of Ala25 with serine. The finding that the ara-C-induced activity is inhibited by the pseudosubstrate PKC(19-36) supports the activation of a PKC-like enzyme. Because PKC can act upstream of the mitogen-activated protein (MAP) kinases, we studied the effects of ara- C treatment on MAP kinase activity. The results demonstrate that MAP kinase is activated in ara-C-treated cells and that the kinetics of this activation are similar to those of the PKC-like activity. Because 12-O-tetradecanoylphorbol-13-acetate has little, if any, effect on the PKC-like and MAP kinase activities in HL-525 cells, these findings suggest that ara-C activates a distinct signaling cascade that may contribute to induction of the c-jun gene.
This article has been cited by other articles:
|
|
 |
|
  X. F. Hu, A. Slater, P. Kantharidis, D. Rischin, S. Juneja, R. Rossi, G. Lee, J. D. Parkin, and J. R. Zalcberg Altered Multidrug Resistance Phenotype Caused by Anthracycline Analogues and Cytosine Arabinoside in Myeloid Leukemia Blood, June 15, 1999; 93(12): 4086 - 4095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Wang, G. Van Tuyle, D. Conrad, P. B. Fisher, P. Dent, and S. Grant Dysregulation of the Cyclin-dependent Kinase Inhibitor p21 WAF1/CIP1/MDA6 Increases the Susceptibility of Human Leukemia Cells (U937) to 1-{beta}-D-Arabinofuranosylcytosine-mediated Mitochondrial Dysfunction and Apoptosis Cancer Res., March 1, 1999; 59(6): 1259 - 1267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. D. Jarvis, F. A. Fornari Jr., R. M. Tombes, R. K. Erukulla, R. Bittman, G. K. Schwartz, P. Dent, and S. Grant Evidence for Involvement of Mitogen-Activated Protein Kinase, Rather than Stress-Activated Protein Kinase, in Potentiation of 1-beta -D-Arabinofuranosylcytosine-Induced Apoptosis by Interruption of Protein Kinase C Signaling Mol. Pharmacol., November 1, 1998; 54(5): 844 - 856. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. P. Whitman, F. Civoli, and L. W. Daniel Protein Kinase Cbeta II Activation by 1-beta -D-Arabinofuranosylcytosine Is Antagonistic to Stimulation of Apoptosis and Bcl-2alpha Down-regulation J. Biol. Chem., September 19, 1997; 272(38): 23481 - 23484. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
